Next report date
Report period
Q1 2024
EPS estimate
−0.07EUR
Revenue estimate
32.92 MEUR
−0.775EUR
−41.69 MEUR
107.92 MEUR
38.11 M
About CALLIDITAS THERAPEUTICS AB
Sector
CEO
Renée Julie Elisabet Aguiar-Lucander
Headquarters
Stockholm
Website
Employees (FY)
217
Founded
2004
ISIN
SE0010441584
FIGI
BBG00LCXC281
Calliditas Therapeutics AB clinical-stage biopharmaceutical company. It engages in the identification, development, and commercialization of novel treatments in orphan indications. The firm focuses on renal and hepatic diseases with significant unmet medical needs. It offers Nefecon, a proprietary, novel oral formulation of budesonide for the treatment of the autoimmune renal disease IgA nephropathy, or IgAN. The firm product TARPEYO is used to reduce proteinuria in adults with primary immunoglobulin. The company was founded by Mikael Bender and Bengt Åke Julander on February 20, 2004 and is headquartered in Stockholm, Sweden.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange CALLIDITAS THERAPEUTICS stocks are traded under the ticker LC8.
CALLIDITAS THERAPEUTICS is going to release the next earnings report on May 7, 2024. Keep track of upcoming events with our Earnings Calendar.
LC8 earnings for the last quarter are −0.01 EUR per share, whereas the estimation was −0.06 EUR resulting in a 76.18% surprise. The estimated earnings for the next quarter are −0.08 EUR per share. See more details about CALLIDITAS THERAPEUTICS earnings.
CALLIDITAS THERAPEUTICS revenue for the last quarter amounts to 25.42 M EUR despite the estimated figure of 28.06 M EUR. In the next quarter revenue is expected to reach 32.23 M EUR.
Yes, you can track CALLIDITAS THERAPEUTICS financials in yearly and quarterly reports right on TradingView.
LC8 net income for the last quarter is −1.64 M EUR, while the quarter before that showed −14.52 M EUR of net income which accounts for 88.69% change. Track more CALLIDITAS THERAPEUTICS financial stats to get the full picture.
No, LC8 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, LC8 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CALLIDITAS THERAPEUTICS stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 26, 2024, the company has 217.00 employees. See our rating of the largest employees — is CALLIDITAS THERAPEUTICS on this list?
We've gathered analysts' opinions on CALLIDITAS THERAPEUTICS future price: according to them, LC8 price has a max estimate of 25.56 EUR and a min estimate of 7.66 EUR. Read a more detailed CALLIDITAS THERAPEUTICS forecast: see what analysts think of CALLIDITAS THERAPEUTICS and suggest that you do with its stocks.